leukemia

[Leukemia] Scientists systematically analyzed genetic alterations in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia uniformly treated in clinical trials with dasatinib-based regimens or a ponatinib-based regimen.

[iScience] The authors found that Reh acute lymphoblastic leukemia cells bearing the KRAS-G12D mutation showed increased proliferation rates in vitro but displayed severely compromised growth in mice.

[Experimental Hematology] Investigators performed targeted panel sequencing of paired diagnostic and first treatment evaluation samples in 69 patients with residual disease by morphology or measurable residual disease level >0.02.

[Cancer Research] Researchers showed in Pax5+/- mice that transient, early-life administration of clinically relevant doses of ruxolitinib, a JAK1/2 inhibitor, significantly mitigated the risk of B cell acute lymphoblastic leukemia following exposure to infection.

[Oncology Research] Investigators directed a study to deepen the effects of nutrient shortage on BCR/Ablprotein expression and signaling in chronic myeloid leukemia cells.

[Blood Advances] Researchers provided insight into the relapsed or refractory (R/R) AML molecular profile and the impact of FLT3 inhibitors on mutational evolution associated with treatment resistance and benefit of gilteritinib across a wide spectrum of molecular and genetic subgroups in FLT3-mutated R/R AML.